Abstract: The technology described herein is directed to stromal-free methods of NK cell differentiation. Also described herein are cells differentiated using stromal-free methods and compositions comprising such cells. In some embodiments, the cells can be genetically modified. In some embodiments, the cells or compositions comprising said cells can be administered to a patient to treat cancer or as a cellular replacement therapy to treat a condition.
Type:
Application
Filed:
March 4, 2022
Publication date:
May 16, 2024
Applicant:
The Children's Medical Center Corporation
Abstract: The present embodiments provide for an immunogenic multiple antigen presenting system comprising a polymer to which antigens are associated by complementary affinity molecules. For example, the polymer can be a polysaccharide, or antigenic polysaccharide, to which protein or peptide antigens from the same or different pathogens are indirectly linked. The present immunogenic compositions can elicit both humoral and cellular immune responses to one or multiple antigens at the same time.
Abstract: The present invention relates generally to methods for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of a small-molecule autophagy modulator for treatment of ribosomal disorders and ribosomopathy. The invention also relates to small molecule drug discovery and methods of screening compositions to determine their effectiveness for treatment of ribosomal disorders and ribosomopathies.
Type:
Grant
Filed:
June 8, 2017
Date of Patent:
May 14, 2024
Assignee:
THE CHILDREN'S MEDICAL CENTER CORPORATION
Abstract: The disclosure provides compositions comprising intercellular adhesion molecule 1 (ICAM1) antibody and methods for using the same for therapeutic applications, for example, treating triple negative breast cancer (TNBC) and predicting drug response.
Abstract: Provided herein are adjuvantation systems comprising fungal polysaccharides for use in Beta coronavirus (e.g., MERS-CoV, SARS-CoV-1, or SARS-CoV-2) and influenza (influenza A virus and influenza B virus) vaccines and immunogenic compositions comprising the adjuvantation system and a Beta coronavirus or influenza virus antigen.
Type:
Application
Filed:
March 11, 2022
Publication date:
May 9, 2024
Applicant:
Children's Medical Center Corporation
Inventors:
Ivan Zanoni, Francesco Borriello, Ofer Levy, David J. Dowling
Abstract: Described herein are compositions (e.g. cells and transgenic animals) and methods relating to engineered Ig loci that permit expression of particular antibodies or antibody segments while still permitting recombination and/or maturation process for antibody optimization.
Type:
Grant
Filed:
June 25, 2018
Date of Patent:
May 7, 2024
Assignee:
CHILDREN'S MEDICAL CENTER CORPORATION
Inventors:
Frederick W. Alt, Hwei-Ling Cheng, Ming Tian
Abstract: The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.
Abstract: Provided herein are cyclic prosaposin peptides and compositions and uses thereof. Exemplary uses include use in the treatment of cancer or in the treatment of inflammatory diseases or disorders.
Abstract: Systems and methods are disclosed herein for quantitatively identifying a patient's sedation level and predicting adverse events, based on one or more capnograms or outputs from a pharmacokinetic, pharmacodynamic, or ventilatory model. A sensor measures a carbon dioxide concentration of air exhaled by a patient into a breath receiver. A processor processes the sensor data to generate a capnogram including one or more respiratory cycles, computes the outputs of pharmacokinetic, pharmacodynamic, or ventilatory models, and extracts one or more of the resulting features from the capnogram and pharmacokinetic, pharmacodynamic, or ventilatory model outputs. A multi-parameter metric is computed based on the one or more extracted features and estimates the current or predicted sedation level of the patient.
Type:
Grant
Filed:
June 26, 2019
Date of Patent:
April 30, 2024
Assignees:
Massachusetts Institute of Technology, Children's Medical Center Corporation
Inventors:
George Cheeran Verghese, Margaret Gan Guo, Rebecca Mieloszyk, Thomas Heldt, Baruch Shlomo Krauss
Abstract: A repair device for closing a valve of a heart includes a main stem. The mains stem has a distal end and a proximal end. The main stem comprises a papillary anchor on the proximal end. The papillary anchor of the main stem is configured to attach to a papillary muscle of the heart. The main stem further includes a first branch extending from the main stem in a first direction and configured to attach to a first leaflet of the valve of the heart. The main stem also includes a second branch extending from the main stem in a second direction different from the first direction and configured to attach to a second leaflet of the valve. The first and second branches are flexible.
Type:
Grant
Filed:
July 11, 2019
Date of Patent:
April 30, 2024
Assignee:
Children's Medical Center Corporation
Inventors:
Peter E. Hammer, David Hoganson, Mossab Y. Saeed, Pedro J. Del Nido, Christopher W. Baird, Sitaram M. Emani
Abstract: A replacement heart valve device is disclosed. In some embodiments, the device includes a frame coupled to one or more leaflets that are moveable between open and closed configurations. In some embodiments, the frame comprises at least two frame sections that join at a pair of commissural posts. In some embodiments, the device may be geometrically accommodating to adapt to different vasculature shapes and sizes and/or to be able to change size while implanted within a growing patient.
Type:
Grant
Filed:
July 13, 2023
Date of Patent:
April 30, 2024
Assignee:
The Children's Medical Center Corporation
Inventors:
Sophie-Charlotte Hofferberth, Pedro J. del Nido, Mossab Y. Saeed
Abstract: The invention features compositions and methods for delivering antibodies to the fetal circulation to be used for preventing and/or treating a fetal alloimmune disorder and/or to treat and/or prevent perinatal infections and/or to prevent neonatal necrotizing enterocolitis.
Type:
Application
Filed:
December 21, 2023
Publication date:
April 18, 2024
Applicant:
The Children's Medical Center Corporation
Abstract: The present invention provides compositions and methods for the treatment or prevention of a neurological disease or disorder of the central nervous system (e.g., a storage disorder, lysosomal storage disorder, neurodegenerative disease, etc.) by reconstitution of brain myeloid cell and microglia upon transplantation of hematopoietic cells enriched in microglia reconstitution potential. The invention also provides compositions and methods for ablating and reconstituting microglia.
Type:
Grant
Filed:
October 16, 2017
Date of Patent:
April 16, 2024
Assignees:
CHILDREN'S MEDICAL CENTER CORPORATION, OSPEDALE SAN RAFFAELE S.R.L., POLITECNICO DI MILANO, FONDAZIONE TELETHON ETS, DANA-FARBER CANCER INSTITUTE, INC
Abstract: Provided herein are nanoparticles which enhance the immunogenicity of antigens for use in Beta coronavirus (e.g., MERS-CoV, SARS-CoV-1, or SARS-CoV-2) vaccines, as well as immunogenic compositions comprising the antigen nanoparticles and additional adjuvants for further enhancing immunogenicity.
Type:
Application
Filed:
June 23, 2022
Publication date:
April 11, 2024
Applicants:
Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
Inventors:
Francesco Borriello, Ofer Levy, David J. Dowling, Sirano Dhe-Paganon, Hyuk-Soo Seo
Abstract: Described herein are modified integrin ? and/or ? headpiece polypeptides, and crystallizable integrin polypeptide dimers comprising a modified integrin ? and/or ? headpiece polypeptide and a disulfide bond linking the two integrin headpiece polypeptide subunits. Methods for using the modified integrin ? and/or ? headpiece polypeptides and the integrin polypeptide dimers are also provided herein. For example, methods for characterizing integrin-ligand interaction and identifying integrin ligands are also provided herein. In some embodiments, the identified integrin ligands can be used as inhibitors of integrins.
Type:
Application
Filed:
September 29, 2023
Publication date:
April 11, 2024
Applicant:
The Children's Medical Center Corporation
Inventors:
Timothy Alan Springer, Xianchi Dong, Chafen Lu
Abstract: The invention features panels of genes associated with Sudden Unexpected Death in Pediatrics (SUDP), and methods of using such panels to identify a cause of death, and to select children at risk of SUDP for therapies to treat pathologies that predispose them to SUDP.
Type:
Application
Filed:
December 7, 2023
Publication date:
April 11, 2024
Applicant:
The Children's Medical Center Corporation
Abstract: The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.
Type:
Grant
Filed:
February 12, 2021
Date of Patent:
April 2, 2024
Assignees:
THE CHILDREN'S MEDICAL CENTER CORPORATION, DANA-FARBER CANCER INSTITUTE, INC.
Inventors:
James Bradner, Jun Qi, Dennis Buckley, Leonard I. Zon, Elizabeth Macari
Abstract: A system includes a sensor configured to generate thoracic impedance data associated with a patient for a period of time, a memory storing machine-readable instructions, and a control system communicatively coupled to the sensor. The control system is arranged to provide control signals to one or more electronic devices and including one or more processors configured to execute the machine-readable instructions to analyze the generated thoracic impedance data associated with the patient; determine, based at least in part on the analysis, respiratory function signals and cardiac function signals, and whether the respiratory function signals and cardiac function signals satisfies a predetermined threshold, and cause an operation of the one or more electronic devices to be modified in response to determining the respiratory function signals and cardiac function signals satisfies the predetermined threshold.
Type:
Application
Filed:
October 8, 2020
Publication date:
March 28, 2024
Applicant:
THE CHILDREN'S MEDICAL CENTER CORPORATION
Abstract: The present invention relates generally to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of calmodulin inhibitors and calcium channel blockers for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA).
Abstract: Methods for preparing and using collagen extracts and collagen scaffolds are provided. Additionally, methods and related kits for the repair of articular tissue using the collagen material are provided.
Type:
Application
Filed:
November 27, 2023
Publication date:
March 21, 2024
Applicant:
The Children's Medical Center Corporation